Lapses at Big Drug Factories Add to Shortages and Danger by Katie Thomas. The New York Times. October 17, 2012.
This article puts forward the idea that drug safety issues extend far beyond the compounding pharmacy involved in the current outbreak of meningitis. While manufacturers reject the notion that production quality is deteriorating, there are areas of concern cited by the article. For example a congressional report claims that a third of the pharmaceutical manufacturing capacity is off line due to quality issues. Industry spokesmen cite continuing efforts to improve operations and safety in response to FDA concerns.
No comments:
Post a Comment